JOHNSON & JOHNSON (JNJ.DE) Fundamental Analysis & Valuation

FRA:JNJ • US4781601046

Current stock price

196.26 EUR
+4 (+2.08%)
Last:

This JNJ.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. JNJ.DE Profitability Analysis

1.1 Basic Checks

  • JNJ had positive earnings in the past year.
  • In the past year JNJ had a positive cash flow from operations.
  • In the past 5 years JNJ has always been profitable.
  • In the past 5 years JNJ always reported a positive cash flow from operatings.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 13.46%, JNJ belongs to the top of the industry, outperforming 89.80% of the companies in the same industry.
  • With a decent Return On Equity value of 32.87%, JNJ is doing good in the industry, outperforming 79.59% of the companies in the same industry.
  • JNJ has a better Return On Invested Capital (15.05%) than 75.51% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for JNJ is in line with the industry average of 14.21%.
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROIC 15.05%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)15.58%
ROIC(5y)14.64%
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • With an excellent Profit Margin value of 28.46%, JNJ belongs to the best of the industry, outperforming 93.88% of the companies in the same industry.
  • JNJ's Profit Margin has improved in the last couple of years.
  • JNJ's Operating Margin of 28.55% is fine compared to the rest of the industry. JNJ outperforms 75.51% of its industry peers.
  • JNJ's Operating Margin has improved in the last couple of years.
  • The Gross Margin of JNJ (67.98%) is comparable to the rest of the industry.
  • JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.55%
PM (TTM) 28.46%
GM 67.98%
OM growth 3Y-0.34%
OM growth 5Y3.01%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.62%
GM growth 5Y0.68%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. JNJ.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so JNJ is still creating some value.
  • Compared to 1 year ago, JNJ has about the same amount of shares outstanding.
  • The number of shares outstanding for JNJ has been reduced compared to 5 years ago.
  • The debt/assets ratio for JNJ is higher compared to a year ago.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • JNJ has an Altman-Z score of 4.89. This indicates that JNJ is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of JNJ (4.89) is better than 75.51% of its industry peers.
  • The Debt to FCF ratio of JNJ is 2.43, which is a good value as it means it would take JNJ, 2.43 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 2.43, JNJ is doing good in the industry, outperforming 77.55% of the companies in the same industry.
  • JNJ has a Debt/Equity ratio of 0.56. This is a neutral value indicating JNJ is somewhat dependend on debt financing.
  • JNJ has a Debt to Equity ratio (0.56) which is comparable to the rest of the industry.
  • Even though the debt/equity ratio score it not favorable for JNJ, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Altman-Z 4.89
ROIC/WACC1.54
WACC9.8%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.3 Liquidity

  • JNJ has a Current Ratio of 1.03. This is a normal value and indicates that JNJ is financially healthy and should not expect problems in meeting its short term obligations.
  • JNJ's Current ratio of 1.03 is on the low side compared to the rest of the industry. JNJ is outperformed by 65.31% of its industry peers.
  • A Quick Ratio of 0.77 indicates that JNJ may have some problems paying its short term obligations.
  • JNJ has a worse Quick ratio (0.77) than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.77
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. JNJ.DE Growth Analysis

3.1 Past

  • JNJ shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.77%.
  • The Earnings Per Share has been growing slightly by 6.11% on average over the past years.
  • JNJ shows a small growth in Revenue. In the last year, the Revenue has grown by 7.87%.
  • The Revenue has been growing slightly by 2.67% on average over the past years.
EPS 1Y (TTM)6.77%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%-2.53%
Revenue 1Y (TTM)7.87%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.91%

3.2 Future

  • Based on estimates for the next years, JNJ will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.75% on average per year.
  • The Revenue is expected to grow by 6.80% on average over the next years.
EPS Next Y7.91%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
EPS Next 5Y9.75%
Revenue Next Year7.43%
Revenue Next 2Y6.86%
Revenue Next 3Y6.73%
Revenue Next 5Y6.8%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

2

4. JNJ.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 21.50, the valuation of JNJ can be described as rather expensive.
  • The rest of the industry has a similar Price/Earnings ratio as JNJ.
  • JNJ is valuated rather cheaply when we compare the Price/Earnings ratio to 27.15, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 18.18, which indicates a rather expensive current valuation of JNJ.
  • JNJ's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.12, JNJ is valued at the same level.
Industry RankSector Rank
PE 21.5
Fwd PE 18.18
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • JNJ's Enterprise Value to EBITDA ratio is in line with the industry average.
  • 61.22% of the companies in the same industry are cheaper than JNJ, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 28.2
EV/EBITDA 16.13
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates JNJ does not grow enough to justify the current Price/Earnings ratio.
  • JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.72
PEG (5Y)3.52
EPS Next 2Y8.38%
EPS Next 3Y8.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. JNJ.DE Dividend Analysis

5.1 Amount

  • JNJ has a Yearly Dividend Yield of 2.32%.
  • JNJ's Dividend Yield is a higher than the industry average which is at 1.96.
  • Compared to an average S&P500 Dividend Yield of 1.82, JNJ pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.32%

5.2 History

  • On average, the dividend of JNJ grows each year by 7.68%, which is quite nice.
Dividend Growth(5Y)7.68%
Div Incr Years7
Div Non Decr Years7
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 46.19% of the earnings are spent on dividend by JNJ. This is a bit on the high side, but may be sustainable.
  • The dividend of JNJ is growing, but earnings are growing more, so the dividend growth is sustainable.
DP46.19%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

JNJ.DE Fundamentals: All Metrics, Ratios and Statistics

JOHNSON & JOHNSON

FRA:JNJ (4/28/2026, 5:15:41 PM)

196.26

+4 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-14
Earnings (Next)07-14
Inst Owners75.61%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap472.71B
Revenue(TTM)96.36B
Net Income(TTM)26.80B
Analysts76.25
Price Target208.28 (6.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.32%
Yearly Dividend4.39
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years7
Div Non Decr Years7
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)3.72%
PT rev (3m)13.96%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)-0.24%
EPS NY rev (1m)0.06%
EPS NY rev (3m)0.82%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE 21.5
Fwd PE 18.18
P/S 5.9
P/FCF 28.2
P/OCF 22.64
P/B 6.81
P/tB N/A
EV/EBITDA 16.13
EPS(TTM)9.13
EY4.65%
EPS(NY)10.8
Fwd EY5.5%
FCF(TTM)6.96
FCFY3.55%
OCF(TTM)8.67
OCFY4.42%
SpS33.29
BVpS28.82
TBVpS-6.23
PEG (NY)2.72
PEG (5Y)3.52
Graham Number76.9377 (-60.8%)
Profitability
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROCE 18.53%
ROIC 15.05%
ROICexc 17.35%
ROICexgc 70.6%
OM 28.55%
PM (TTM) 28.46%
GM 67.98%
FCFM 20.91%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)15.58%
ROIC(5y)14.64%
ROICexc(3y)18.74%
ROICexc(5y)17.83%
ROICexgc(3y)70.93%
ROICexgc(5y)71.82%
ROCE(3y)18.94%
ROCE(5y)17.92%
ROICexgc growth 3Y-2.46%
ROICexgc growth 5Y-5.65%
ROICexc growth 3Y1.88%
ROICexc growth 5Y1.69%
OM growth 3Y-0.34%
OM growth 5Y3.01%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.62%
GM growth 5Y0.68%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Debt/EBITDA 1.34
Cap/Depr 64.4%
Cap/Sales 5.13%
Interest Coverage 7
Cash Conversion 71.32%
Profit Quality 73.49%
Current Ratio 1.03
Quick Ratio 0.77
Altman-Z 4.89
F-Score4
WACC9.8%
ROIC/WACC1.54
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)6.77%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%-2.53%
EPS Next Y7.91%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
EPS Next 5Y9.75%
Revenue 1Y (TTM)7.87%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.91%
Revenue Next Year7.43%
Revenue Next 2Y6.86%
Revenue Next 3Y6.73%
Revenue Next 5Y6.8%
EBIT growth 1Y15.95%
EBIT growth 3Y5.24%
EBIT growth 5Y5.76%
EBIT Next Year23.27%
EBIT Next 3Y11.78%
EBIT Next 5Y9.67%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%

JOHNSON & JOHNSON / JNJ.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE.


What is the valuation status of JOHNSON & JOHNSON (JNJ.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


How profitable is JOHNSON & JOHNSON (JNJ.DE) stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 7 / 10.


What is the financial health of JOHNSON & JOHNSON (JNJ.DE) stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10.


Can you provide the expected EPS growth for JNJ stock?

The Earnings per Share (EPS) of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 7.91% in the next year.